FDA Approves Avapritinib for Indolent Systemic Mastocytosis

On May 22, the U.S. Food and Drug Administration (FDA) approved avapritinib for the treatment of adults with indolent systemic mastocytosis.

For more information, read the Blueprint Medicines announcement.

Posted 5/24/2023